Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems Inc. is positioned for growth in the oncology market, primarily through the ongoing expansion of treatment centers and positive expectations surrounding CHOPIN data, which may enhance the adoption of its product, Hepzato. Financially, while projected total revenues are expected to decline to $343 million in 2032 from a prior forecast of $431 million, margin improvements are anticipated to sustain and potentially grow the company's bottom line. Additionally, the firm is on track to expand its presence with 25-28 sites expected by the end of 2025, supported by strong clinical data from the FOCUS trial, indicating a strong outlook for future sales.

Delcath Systems Inc. has reported a 15% sequential decline in total revenues for the third quarter of 2025, resulting in preliminary revenues of $20.5 million, which fall below consensus estimates of $23.8 million. The company has significantly reduced its full-year revenue guidance to a range of $83-$85 million from $93-$96 million, reflecting challenges such as reduced new site activations, summer seasonality effects, and competitive clinical trials, all contributing to a steep decrease in new patient starts. Additionally, management's revised revenue estimates for 2026 have also been lowered, indicating ongoing concerns about revenue growth and operational performance in the near term.